New 'Double Punch' drug takes on advanced tumors

NCT ID NCT07016490

Recruiting now Disease control Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called SSGJ-709 in 15 people with advanced cancers that have spread. The drug is designed to block two immune system brakes (PD-1 and LAG-3) at once, potentially helping the body fight tumors. The main goals are to check safety and how the drug moves through the body, with a preliminary look at whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SSGJ-709 (a bispecific antibody that targets two immune checkpoints, PD-1 and LAG-3)
What this could lead to: If this early trial shows safety and hints of tumor shrinkage, it could lead to a new treatment option for advanced cancers that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) and small (15 participants) study focused on safety, not effectiveness. The drug may cause side effects or fail to shrink tumors. Results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANT TUMORS

Contacts and locations

Locations

Southern Oncology Clinical Research Unit (SOCRU)
RECRUITING

Adelaide, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.